received by the International Bureau on 03 October 2016 (03.10.2016)

CLAIMS

Claims

1. (Original) A method for inhibiting a rotavirus infection in a subject, comprising

administering to said subject exhibiting at least one symptom of a rotavirus infection a pharmaceutically effective amount of at least one purified prenylated stilbenoid, under conditions such that said at least one symptom of a rotavirus infection is reduced.

2. (Original) The method of claim 1, wherein said at least one prenylated stilbenoid

comprises a combination of prenylated stilbenoids.

3. (Original) The method of claim 1, wherein said at least one prenylated stilbenoid is a purified stilbenoid.

4. (Original) The method of claim 1 , whei-ein said at least one prenylated stilbenoid comprises an extract of hairy root cultures of the peanut plant.

5. (Original) The method of claim 1, wherein said at least one prenylated stilbenoid comprises an enriched fraction of a stilbenoid extract.

6. (Original) The method of claim 1, wherein said prenylated stilbenoid is selected from the group consisting of arachidin-1 and arachidin-3.

7. (Original) The method of claim 1, wherein said prenylated stilbenoid is purified from a biological system.

8. (Original) The method of claim 5, wherein said extract enriched in prenylated

stilbenoids is obtained from a biological system.

9. (Currently Amended) The method of claims 7 or 8, wherein said biological system is a hairy root culture.

10. (Original) The method of claim 1, wherein said prenylated stilbenoid is produced synthetically.

37

11. (Original) The method of claim 1 , wherein said prenylated stilbenoid modulates at least one cannabinoid receptor

12. (Original) The method of claim 11, wherein said modulation of at least one cannabinoid receptor reduces virus replication.

13. (Currently Amended) The method of claim 1, where said prenylated stilbenoid regulates the apoptosis and autophagy pathways in virus infected cells.

14. (Currently Amended) The method of claim 13, where said regulation between the

apoptosis and autophagy pathways reduces virus replication.

15. (Original) The method of claim 1, wherein said administering is intravenous.

16. (Original) The method of claim 1, wherein said administering is intraperitoneal.

17. (Original) The method of claim 1, wherein said administering is oral.